The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting ... Purpose 1 · Purpose 2 · Purpose 3 · Purpose 4

24 июл. 2024 г. · We evaluated the safety and efficacy of twice-yearly subcutaneous lenacapavir or daily oral F/TAF for HIV prevention in adolescent girls and young women.

PURPOSE 1, which enrolled cisgender women, will evaluate an investigational drug, lenacapavir, and an FDA-approved PrEP drug for people assigned male at birth.

12 сент. 2024 г. · The study evaluated the safety and efficacy of twice-yearly injectable lenacapavir for PrEP compared to once-daily oral emtricitabine/tenofovir ...

5 авг. 2024 г. · This factsheet provides a summary of the PURPOSE 1 phase III clinical trial of lenacapavir for PrEP and F/TAF for cisgender women taking place in South Africa ...

20 июн. 2024 г. · The PURPOSE program comprises five HIV prevention trials around the world that are focused on innovation in science, trial design, community ...

12 сент. 2024 г. · The study evaluated the safety and efficacy of twice-yearly injectable lenacapavir for PrEP compared to once-daily oral emtricitabine/tenofovir ...

26 сент. 2024 г. · The PURPOSE 2 trial reported a 96% reduction in the risk of acquiring HIV among study participants, with 99.9% of individuals using LEN not ...

13 нояб. 2024 г. · The program comprises five HIV prevention trials around the world that are focused on innovation in science, trial design, community engagement ...

PURPOSE 1-5 is the most comprehensive and diverse program for an investigational HIV PrEP program ever conducted. More information about the PURPOSE program can ...